Kura Oncology's Ziftomenib Shows Strong Long-Term AML Data, Boosting Phase 3 Trial Prospects
Event summary
- Kura Oncology and Kyowa Kirin reported 12-month overall survival rates of 94% for NPM1-m AML and 71% for KMT2A-r AML patients in the KOMET-007 trial.
- Composite remission rates reached 96% in NPM1-m AML and 90% in KMT2A-r AML, with high MRD negativity rates.
- Median overall survival was not reached in either patient subset with median follow-up of 17.6 months and 11.0 months, respectively.
- The data compare favorably to historical 7+3 chemotherapy benchmarks, strengthening confidence in the ongoing Phase 3 KOMET-017 trial.
- Kura will host a virtual investor event on June 12, 2026, to discuss the results.
The big picture
The strong long-term data from the KOMET-007 trial position ziftomenib as a potential foundational therapy in frontline AML, addressing a high-unmet need in a disease with historically poor outcomes. The results suggest the combination of ziftomenib with standard chemotherapy could reduce reliance on transplant, a significant advancement in AML treatment. The ongoing Phase 3 trial will be critical in determining whether these promising results can be replicated at scale and support regulatory approval.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 KOMET-017 trial can successfully leverage these data to secure regulatory approval for ziftomenib in frontline AML.
- Competitive Positioning
- How these results position ziftomenib against emerging menin inhibitors and other targeted therapies in AML.
- Commercial Strategy
- The pace at which Kura and Kyowa Kirin can translate these clinical successes into market adoption and revenue growth.